TOVX (Theriva Biologics) Accounting Capitalization

Theriva Biologics, Inc. (TOVX) develops oncolytic viruses to combat gastrointestinal tumors, leveraging long-term patents and government procurement. Business success is based on patient survival rates and partner support, with the current metric standing at 0.01. A stable staff of leading oncologists and manufacturing experts ensures R&D continuity. The following charts illustrate the price evolution of the company's shares.

therivabio.com (TOVX): Company Book Value from 04/28/2023 to 10/31/2026

TOVX (Theriva Biologics): analytical breakdowns and indicator data

- share price and expert price forecast:

Price Chart Theriva Corp|TOVX - Consensus Target

- business market valuation indicators:

Market Capitalization Theriva Biologics Inc|TOVX - Total Company Value

- book capitalization indicators:

Net Asset Value per Share Theriva Biologics|TOVX - Company Book Value|Capitalization to Book Value Ratio therivabio.com|TOVX - Company Total Assets

- debt and liquidity data:

- net income and valuation ratios data:

TOVX - Net Income

Initial company analysis:Theriva Corp - TOVX

Manufactured product of Theriva Biologics, Inc.

Book value capitalization determines the net asset value minus all liabilities, capturing the actual volume of equity as a guarantee for investment protection. The current book value of capital at 0.01 reflects the financial stability of Theriva Biologics, Inc., confirming the company's ability to maintain costly temperature control infrastructure and biologics logistics for oncology research.

Competitor analysis